Navigation Links
InterMune Reports Second Quarter 2014 Financial Results and Business Highlights
Date:8/6/2014

mately $85-$90 million.

Total Operating Expenses (R&D and SG&A):  Currently anticipated to be in a range of $380 to $400 million (previously $320 to $345 million).

Conference Call and Webcast DetailsInterMune will host a live webcast of a conference call today at 4:30 p.m. EDT to discuss financial results and business highlights for the second quarter 2014.  Interested stockholders and others may participate in the conference call by dialing 800-728-2056 (U.S.) or +1 212-231-2900 (international), conference ID# 21728775.  A replay of the webcast and teleconference will be available approximately three hours after the call.

To access the webcast, please log on to the company's website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

A telephonic replay will be available for 10 business days following the call and can be accessed by dialing 800-633-8284 (U.S.) or +1 402-977-9140 (international), and entering the conference ID# 21728775.  The webcast will remain available on the company's website until the next earnings call.

About InterMune InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases.  In pulmonology, InterMune is focused on therapies for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  Pirfenidone is approved for marketing by InterMune in the EU and Canada as Esbriet®.  Pirfenidone is not approved for marketing in the United States.  InterMune resubmitted the pirfenidone New Drug Application (NDA) to the U.S. FDA on May 23, 2014, to support regulatory registration in the United States.  The resubmission has been accepted by the FDA and assigned a target PDUFA date
'/>"/>

SOURCE InterMune, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. The Zacks Analyst Blog Highlights: Anthera Pharmaceuticals, Amgen, Eli Lilly, Actelion and InterMune
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Reports Second Quarter 2013 Financial Results And Business Highlights
4. Sean P. Nolan Joins InterMune as Executive Vice President and Chief Business Officer
5. InterMune Announces Presentations of New Research in IPF at ERS
6. InterMune Reports Second Quarter 2012 Financial Results and Business Highlights
7. InterMune to Divest Actimmune® (Interferon Gamma-1b)
8. Neurocrine Biosciences Reports Second Quarter 2014 Results
9. Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2015
10. China Biologic Reports Financial Results for the Second Quarter of 2014
11. Avanir Pharmaceuticals Reports Fiscal 2014 Third Quarter Financial and Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015 OmniSeq, LLC today ... to the OmniSeq SM Genomic Network.  Recently, ... Institute (RPCI) and announced it was making available ... physician-driven, collaborative approach to genomic diagnostics that provides ... Institute is a rapidly expanding, multidisciplinary cancer care ...
(Date:8/3/2015)... , Aug. 3, 2015  Depomed, Inc. (NASDAQ: ... on Horizon Pharma plc,s (NASDAQ: HZNP ) ("Horizon") ... of Directors ("Depomed Board") set a record date to ... The Depomed Board will review the ... is received today and contains the information required under ...
(Date:8/3/2015)... , August 3, 2015 ... expected to reach USD 24.7 billion by 2022, ... Research Inc. Growing prevalence of neurological and musculoskeletal ... market over the forecast period. The presence of ... cryotherapy, advancement in the technologies coupled with implementation ...
Breaking Medicine Technology:OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 2OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 3Depomed Comments on Horizon Pharma Announcement 2Depomed Comments on Horizon Pharma Announcement 3Depomed Comments on Horizon Pharma Announcement 4Depomed Comments on Horizon Pharma Announcement 5Depomed Comments on Horizon Pharma Announcement 6Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 3Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 5
... today announced Los Angeles, Calif. as the second stop of ... started in 2010 to raise awareness about asthma and exercise-induced ... percent of children and adults with asthma, and an estimated ... is a treatable condition that causes wheezing, coughing and chest ...
... 2011 Mylan Inc. (Nasdaq: MYL ) today announced ... which will resolve litigation related to Lipitor ® Tablets, 10 ... Atorvastatin Calcium Tablets. The terms of the agreement are confidential, and ... of Justice and the Federal Trade Commission. Lipitor had ...
Cached Medicine Technology:'EIB Active™' Campaign and Celebrity Nanny Jo Frost Kick Off 2011 in Los Angeles to Educate Families About Asthma and Exercise-Induced Bronchospasm (EIB) 2'EIB Active™' Campaign and Celebrity Nanny Jo Frost Kick Off 2011 in Los Angeles to Educate Families About Asthma and Exercise-Induced Bronchospasm (EIB) 3'EIB Active™' Campaign and Celebrity Nanny Jo Frost Kick Off 2011 in Los Angeles to Educate Families About Asthma and Exercise-Induced Bronchospasm (EIB) 4'EIB Active™' Campaign and Celebrity Nanny Jo Frost Kick Off 2011 in Los Angeles to Educate Families About Asthma and Exercise-Induced Bronchospasm (EIB) 5'EIB Active™' Campaign and Celebrity Nanny Jo Frost Kick Off 2011 in Los Angeles to Educate Families About Asthma and Exercise-Induced Bronchospasm (EIB) 6'EIB Active™' Campaign and Celebrity Nanny Jo Frost Kick Off 2011 in Los Angeles to Educate Families About Asthma and Exercise-Induced Bronchospasm (EIB) 7Mylan Announces Lipitor® Settlement Agreement 2
(Date:8/3/2015)... Detroit, Mich (PRWEB) , ... August 03, 2015 , ... ... this country has declined, according to a new publication released today by the AAMC ... of black male college graduates over the past three decades, the number of black ...
(Date:8/3/2015)... ... August 03, 2015 , ... The Workgroup for Electronic Data Interchange ... to create efficiencies in healthcare information exchange, announced the release of its findings from ... Human Services (HHS) Secretary, WEDI shared survey results and recommendations , ...
(Date:8/3/2015)... ... ... to an opinion piece published July 28 by the Washington Post, the conventional ... loss may not be accurate. While this system may work for some people, the author ... based both on the individual and at what point that person is in their weight ...
(Date:8/3/2015)... ... August 03, 2015 , ... Bayer has agreed to pay ... claims in which a claimant alleged to have suffered an arterial blood clot including ... control pills, Yaz, Yasmin and Ocella, has been ongoing for well-over five years. In ...
(Date:8/3/2015)... ... August 03, 2015 , ... BESLER Consulting today announced the ... , The MarketingProfs Bright Bulb B2B Awards celebrate the best marketing, communications, and ... launch of their Readmissions Analytics product was selected as one of four finalists ...
Breaking Medicine News(10 mins):Health News:New Publication Focuses on the Decline of Black Males in Medicine 2Health News:New Publication Focuses on the Decline of Black Males in Medicine 3Health News:New Publication Focuses on the Decline of Black Males in Medicine 4Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 2Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 3Health News:WEDI ICD-10 Survey Results: Industry Nearing Readiness but Physician Practices Lagging Behind 4Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2
... and France signed a landmark cooperative treaty here Thursday ... expected by practitioners to help in the fight against ... cooperate in academic and clinical TCM research, setting new ... practice and developing new TCM products, said the document ...
... city's eastern fringe towards the airport, a signboard on the ... by Maneka Gandhi's People for Animals (PFA). ... day comes true. This sprawling pound aims to restore the ... focuses on anti-rabies vaccination for the canines. ,"We ...
... can prevent [chronic diseases], more people can live longer.',Rapid advances ... are bringing// closer the time when many people can achieve ... Dr. Pascal Goldschmidt, dean of the University of Miami Miller ... we will see diagnostic tools and therapies that will change ...
... in Los Angeles, it was reported that AIDS cases have ... Jaffe, a professor of medicine at Oxford University in England, ... ,He also called for a new approach to ... emphasized on the scientific approach rather than moral and religious ...
... women have been asked to keep a strict watch on ... , The appeal has come from UK’s government watchdog group ... , According to them, one in every seven women ... pregnancy. This refers also to the ‘baby blues’ that quite ...
... it is possible to use a resin filter to ... infected animal, //a finding that has major implications for ... associated with variant Creutzfeldt-Jakob disease, mad cow disease, scrapie ... transfusions. ,Dr. Ruben Carbonell, Frank Hawkins Kenan ...
Cached Medicine News:Health News:An Anti-rabies Campaign With Bite 2Health News:An Anti-rabies Campaign With Bite 3Health News:Genetics Might Engineer Path to Successful Aging 2Health News:'Baby Blues’-no Tiny Proble 2Health News:Researchers Develop Resin Beads That Capture Mad Cow Disease Agent From Blood 2
Speculum can be used for any type of eye surgery. Arms of speculum lie flat due to joint between blade and arms. Features quick locking mechanism....
Pediatric model. Spring-controlled spread of blades with locking mechanism. Dull finish. Blades: 11 mm....
Fenestrated blades with screw-controlled spread. Dull finish. Blades: 15 mm....
Designed for use with foster enucleation snare (E3670). Package of 12 stainless steel wires. Overall length 5.3 inches....
Medicine Products: